University of California San FranciscoNeuroimmunology & Glial Biology

Clinical studies / ReVIVE

ReVIVE

Using MRI to assess changes associated with clemastine as a potential myelin repair therapy in multiple sclerosis.

UCSF lists as accepting participants

Checked October 6, 2026 · NCT05359653 · Phase 1/2

What is the study asking?

Using MRI to assess changes associated with clemastine as a potential myelin repair therapy in multiple sclerosis. This is a randomized, double-blind, placebo-controlled study.

Clemastine is being investigated for myelin repair in this study; it is not approved for this use.

Participation at a glance

Approximate duration
6 months
Minimum visits
3 at UCSF
Typical visit
5 hours

Visit estimates below come from the existing Green Lab overview. Confirm the current schedule with the study team.

Study visit sequence

  1. Screening
  2. Month 3
  3. Month 6

The original lab overview describes two groups: clemastine followed by placebo, or placebo followed by clemastine. Each period lasts three months.

Who may be eligible?

The official listing includes adults ages 18–55 with relapsing-remitting multiple sclerosis and a disease duration of less than 15 years. Additional inclusion and exclusion criteria apply.

Read full criteria on UCSF Clinical Trials

The study team determines eligibility and explains the current protocol, potential risks, and consent process. This overview is not treatment advice.

Ask the study team

Use the official UCSF study page to check availability and contact the team.

Contact the ReVIVE study team

Sources: Green Lab study overview and UCSF Clinical Trials.